Developing drugs that specifically target key molecules in the molecular pathways connecting obesity and HCC, such as inhibitors of NF-κB, PI3K/AKT/mTOR, and PPAR-γ, may prove effective in preventing or treating HCC in obese individuals. This evidence concerns the gene MTOR and obesity disorder.